Automated Summary
Key Facts
Plaintiff Todd MacLaughlan, founder of Delaware corporation Profounda, Inc., alleges that defendants Morris Goodman and others breached fiduciary duties by asserting a claim (the 'Diversion Claim') that he improperly diverted 30% of the profits from the Orphan Drug, a product developed through a licensing agreement with Knight Therapeutics. The Company received $4.5 million in funding from Goodman's affiliate Joddes Limited in exchange for preferred stock. The dispute arose after MacLaughlan used his share of the profits to fund the Company's operations instead of returning them to Goodman. The court dismissed most claims but allowed a declaratory judgment action to proceed, requiring the Company to be named as a merits defendant.
Transaction Type
Distribution and License Agreement for the Orphan Drug
Issues
- Count V tortious interference claim was dismissed as the court lacked personal jurisdiction over Morris and Parent for this claim.
- Counts I and III alleging breach of fiduciary duty by directors were dismissed as the Complaint failed to state claims under the business judgment rule and did not trigger entire fairness review.
- Count II seeking declaration that MacLaughlan retains 30% profit rights under the Oral Profits Agreement was deemed ripe and remains active after repleading to name the Company as a merits defendant.
- The court dismissed Parent's Rule 12(b)(2) motion by finding no substantial Delaware-directed act or effect in furtherance of the alleged conspiracy, failing to meet the Istituto Bancario test for conspiracy jurisdiction.
- Morris' non-director claims (controlling stockholder, conspirator, tortious interferer) were dismissed as the court could not exercise ancillary jurisdiction due to lack of viable director claims.
- Count IV conspiracy claim was dismissed as it failed to establish a primary fiduciary breach required for conspiracy liability.
Holdings
- Count II (declaratory judgment regarding the Oral Profits Agreement) survives dismissal and can proceed against the Company as a merits defendant, as it states a claim ripe for adjudication.
- Morris's motion to dismiss under Rule 12(b)(2) was granted for claims against him in non-director capacities (controlling stockholder, conspirator, tortious interferer) because no viable claim exists against him as a director.
- Counts I, III, and V (breach of fiduciary duty, derivative claims, and conspiracy) were dismissed with prejudice against Orleski, Einheiber, and Morris in his director capacity, as the Complaint fails to state claims on which relief can be granted.
- The court granted Parent's motion to dismiss under Rule 12(b)(2), determining it lacks personal jurisdiction over Parent due to the absence of a Delaware-directed act or sufficient minimum contacts.
Remedies
- Counts I, III, and V are dismissed without prejudice to the extent they assert claims against Parent or Morris in his capacities as a controlling stockholder, conspirator, or tortious interferer. They are dismissed with prejudice to the extent they assert claims against Orleski, Einheiber, or Morris in his capacity as a director. Count IV is dismissed without prejudice.
- Count II seeking a declaratory judgment that MacLaughlan possesses a right to 30% of the profits from the Orphan Drug can proceed. The court orders MacLaughlan to file a second amended complaint within thirty days that names the Company as a merits defendant.
Legal Principles
The court applied Delaware's fiduciary duty principles, emphasizing that directors owe duties to the corporation and its stockholders as a whole, not to individual stockholders in non-stockholder capacities. The decision also discussed the business judgment rule as the default standard of review for director conduct, requiring plaintiffs to overcome presumptions of good faith and rational decision-making. Key aspects included the duty of loyalty, the requirement to act in the best interests of the corporation, and the distinction between fiduciary duties and contractual obligations.
Precedent Name
- RJR Nabisco, Inc. S'holders Litig.
- Crescent/Mach I P'rs, L.P. v. Turner
- Weinberger v. UOP, Inc.
- Disney II (Disney I's affirmance)
- Nemec v. Shrader
- Aronson v. Lewis
- McRitchie v. Zuckerberg
- Disney I (In re Walt Disney Co. Deriv. Litig.)
- In re Columbia Pipeline Gp., Inc. Merger Litig.
- Brehm v. Eisner
Key Disputed Contract Clauses
The Oral Profits Agreement granted MacLaughlan a 30% share of the Orphan Drug's profits, which became central to the dispute over whether these funds were improperly diverted as corporate assets. The court analyzed this clause in the declaratory judgment claim (Count II) to determine its validity and MacLaughlan's entitlement.
Cited Statute
- Director Consent Statute
- Delaware General Corporation Law
- Delaware Long-Arm Statute
Judge Name
Laster
Passage Text
- The allegations against Morris and the two current directors fail to state claims on which relief can be granted. Either MacLaughlan cannot state a claim under the applicable standard of conduct, or his theories fail under the applicable standard of review.
- The court lacks personal jurisdiction over Parent, because it has not engaged in any Delaware-directed act that could support jurisdiction under Delaware's long-arm statute.
- One claim, however, survives. MacLaughlan seeks a declaratory judgment that he did not improperly divert a corporate asset. The Company is both the lone remaining defendant and the proper defendant on this claim.
Damages / Relief Type
Declaratory judgment claim proceeds against the Company as a merits defendant; no monetary damages awarded.